These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

61 related items for PubMed ID: 3771718

  • 1. Determination of desferoxamine and ferrioxamine by high-performance liquid chromatography with direct serum injection and pre-column enrichment.
    van der Horst A, de Goede PN, Willems HJ, van Loenen AC.
    J Chromatogr; 1986 Aug 22; 381(1):185-91. PubMed ID: 3771718
    [No Abstract] [Full Text] [Related]

  • 2. Estimation of aluminoxamine and ferrioxamine in plasma by high performance liquid chromatography.
    Hughes H, Hagen LE, Cameron EC, Sutton RA.
    Clin Chim Acta; 1986 May 30; 157(1):115-20. PubMed ID: 3719992
    [No Abstract] [Full Text] [Related]

  • 3. Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration.
    Menéndez-Fraga P, Fernández-Martín JL, Blanco-González E, Cannata-Andía JB.
    Clin Chem; 1998 Jun 30; 44(6 Pt 1):1262-8. PubMed ID: 9625051
    [Abstract] [Full Text] [Related]

  • 4. High-performance liquid chromatography of deferoxamine and ferrioxamine: interference by iron present in the chromatographic system.
    Cramer SM, Nathanael B, Horváth C.
    J Chromatogr; 1984 Jul 20; 295(2):405-11. PubMed ID: 6432830
    [Abstract] [Full Text] [Related]

  • 5. Quantification of desferrioxamine, ferrioxamine and aluminoxamine by post-column derivatization high-performance liquid chromatography. Non-linear calibration resulting from second-order reaction kinetics.
    Kraemer HJ, Breithaupt H.
    J Chromatogr B Biomed Sci Appl; 1998 Jun 12; 710(1-2):191-204. PubMed ID: 9686887
    [Abstract] [Full Text] [Related]

  • 6. Use of ultrafiltration and chromatography to assess aluminum speciation in serum after deferoxamine administration.
    Canteros-Picotto A, Fernández-Martín JL, Cannata-Andía JB.
    Am J Kidney Dis; 2000 Nov 12; 36(5):969-75. PubMed ID: 11054353
    [Abstract] [Full Text] [Related]

  • 7. Validated HPLC assay for iron determination in biological matrices based on ferrioxamine formation.
    Tesoro A, Novakovic J, Thiessen JJ, Spino M.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Sep 05; 823(2):177-83. PubMed ID: 16023418
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Simultaneous determination of desferrioxamine and ferrioxamine by high-performance liquid chromatography with amperometric detection.
    Glennon JD, Senior AT.
    J Chromatogr; 1990 May 18; 527(2):481-9. PubMed ID: 2117617
    [No Abstract] [Full Text] [Related]

  • 10. Ferrioxamine and its hexadentate iron-chelating metabolites in human post-desferal urine studied by high-performance liquid chromatography and fast atom bombardment mass spectrometry.
    Lehmann WD, Heinrich HC.
    Anal Biochem; 1990 Feb 01; 184(2):219-27. PubMed ID: 2109548
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis.
    Allain P, Mauras Y, Chaleil D, Simon P, Ang KS, Cam G, Le Mignon L, Simon M.
    Br J Clin Pharmacol; 1987 Aug 01; 24(2):207-12. PubMed ID: 3620295
    [Abstract] [Full Text] [Related]

  • 12. Ability to determine the desferrioxamine-chelatable iron fractions of nontransferrin-bound iron using HPLC.
    Koba M, Słomka A, Bączek T, Marszałł MP, Zekanowska E.
    J Sep Sci; 2013 Feb 01; 36(4):665-9. PubMed ID: 23355397
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients.
    Verpooten GA, D'Haese PC, Boelaert JR, Becaus I, Lamberts LV, De Broe ME.
    Nephrol Dial Transplant; 1992 Feb 01; 7(9):931-8. PubMed ID: 1328941
    [Abstract] [Full Text] [Related]

  • 14. Antineuroblastoma activity of desferoxamine in human cell lines.
    Blatt J, Stitely S.
    Cancer Res; 1987 Apr 01; 47(7):1749-50. PubMed ID: 3815370
    [Abstract] [Full Text] [Related]

  • 15. Hepatic transport of magnetic resonance imaging contrast agents. Ferrioxamine B derivatives.
    White DL, Eason RG, Alkire AL, Price DC, Hoener BA, Milco LA, Keen RE, Barnhart JL.
    Invest Radiol; 1991 Nov 01; 26 Suppl 1():S146-7; discussion S150-5. PubMed ID: 1808112
    [No Abstract] [Full Text] [Related]

  • 16. An expedient reverse-phase high-performance chromatography (RP-HPLC) based method for high-throughput analysis of deferoxamine and ferrioxamine in urine.
    Arshad B, Iqbal T, Akram S, Mushtaq M.
    Biomed Chromatogr; 2017 Feb 01; 31(2):. PubMed ID: 27503066
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A high-performance liquid chromatographic method for the measurement of deferoxamine in body fluids.
    Tesoro A, Leeder JS, Bentur Y, Klein J, Freedman M, Koren G.
    Ther Drug Monit; 1989 Feb 01; 11(4):463-70. PubMed ID: 2741196
    [Abstract] [Full Text] [Related]

  • 19. Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection.
    Singh S, Mohammed N, Ackerman R, Porter JB, Hider RC.
    Anal Biochem; 1992 May 15; 203(1):116-20. PubMed ID: 1524206
    [Abstract] [Full Text] [Related]

  • 20. Deferoxamine and autoassay of serum iron.
    Schenken JR, Grass L.
    Clin Toxicol; 1971 Dec 15; 4(4):641-2. PubMed ID: 5164174
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.